Abstract
During the first 6 months of glatiramer acetate therapy in 82 consecutive patients with multiple sclerosis, in only 6% frequency of pre-existing headaches increased by more than 50%. This is less than the headache aggravation reported in an earlier study in up to 35% of patients during the first 6 months on interferon beta.
Publication types
-
Controlled Clinical Trial
MeSH terms
-
Adjuvants, Immunologic / therapeutic use
-
Adult
-
Female
-
Glatiramer Acetate
-
Headache / epidemiology*
-
Headache / etiology*
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Incidence
-
Interferon-beta / therapeutic use
-
Male
-
Middle Aged
-
Multiple Sclerosis / complications*
-
Multiple Sclerosis / drug therapy*
-
Peptides / adverse effects
-
Peptides / therapeutic use*
-
Time Factors
Substances
-
Adjuvants, Immunologic
-
Immunosuppressive Agents
-
Peptides
-
Glatiramer Acetate
-
Interferon-beta